Voyager Therapeutics, Inc. Stock price

Equities

VYGR

US92915B1061

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
9.31 USD -2.62% Intraday chart for Voyager Therapeutics, Inc. -0.96% +10.31%
Sales 2024 * 38.84M Sales 2025 * 51.19M Capitalization 506M
Net income 2024 * -98M Net income 2025 * -106M EV / Sales 2024 * 4.87 x
Net cash position 2024 * 316M Net cash position 2025 * 373M EV / Sales 2025 * 2.58 x
P/E ratio 2024 *
-5.18 x
P/E ratio 2025 *
-5.3 x
Employees 162
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.67%
More Fundamentals * Assessed data
Dynamic Chart
Guggenheim Initiates Voyager Therapeutics With Buy Rating, $22 Price Target MT
H.C. Wainwright Initiates Coverage on Voyager Therapeutics With Buy Rating, $30 Price Target MT
Voyager Therapeutics, Inc.(NasdaqGS:VYGR) added to S&P Biotechnology Select Industry Index CI
Voyager Therapeutics Appoints Toby Ferguson as Chief Medical Officer MT
Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024 CI
Citigroup Starts Voyager Therapeutics With Buy Rating, $16 Price Target MT
Transcript : Voyager Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Voyager Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Voyager Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment CI
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research CI
Certain Restricted Stock Units of Voyager Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2024. CI
Certain Stock Options of Voyager Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2024. CI
Certain Common Stock of Voyager Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2024. CI
Transcript : Voyager Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:45 AM
More news
1 day-2.62%
1 week-0.96%
Current month+11.90%
1 month+3.79%
3 months+5.68%
6 months+20.60%
Current year+10.31%
More quotes
1 week
8.91
Extreme 8.91
10.19
1 month
8.24
Extreme 8.24
10.57
Current year
7.01
Extreme 7.01
11.72
1 year
6.06
Extreme 6.06
14.34
3 years
2.46
Extreme 2.46
14.34
5 years
2.46
Extreme 2.46
28.79
10 years
2.46
Extreme 2.46
31.91
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 22-02-28
Chairman 61 15-07-21
Director of Finance/CFO 55 22-09-18
Members of the board TitleAgeSince
Director/Board Member 75 23-05-08
Director/Board Member 70 13-12-31
Director/Board Member 68 17-01-04
More insiders
Date Price Change Volume
24-03-28 9.31 -2.62% 629,050
24-03-27 9.56 -4.59% 730,077
24-03-26 10.02 +8.21% 882,443
24-03-25 9.26 +2.77% 661,919
24-03-22 9.01 -4.15% 482,896

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.31 USD
Average target price
17.78 USD
Spread / Average Target
+90.95%
Consensus
  1. Stock
  2. Equities
  3. Stock Voyager Therapeutics, Inc. - Nasdaq